AbbVie Says FDA Approves Qulipta as Migraine Treatment
September 28 2021 - 7:30PM
Dow Jones News
By Stephen Nakrosis
AbbVie Inc. on Tuesday said the U.S. Food and Drug
Administration approved Qulipta for the preventive treatment of
episodic migraine in adults.
The company said Qulipta, or atogepant, "demonstrated
statistically significant, clinically meaningful rapid and
continuous reductions in mean monthly migraine days among adults
with episodic migraine compared to placebo."
Michael Severino, vice chairman and president of AbbVie, said
"Millions of people living with migraine often lose days of
productivity each month because attacks can be debilitating.
Qulipta can help by reducing monthly migraine days with a
once-daily, oral dose that works quickly and continuously."
AbbVie said it is the only pharmaceutical company offering three
treatments across the full spectrum of migraine.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 28, 2021 19:15 ET (23:15 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024
